search
Back to results

Randomized Controlled Trial of Stress Reduction and Lifestyle Modification for Ulcerative Colitis (MBMCol)

Primary Purpose

Ulcerative Colitis

Status
Unknown status
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
lifestyle-modification
Control group
Sponsored by
Universität Duisburg-Essen
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Ulcerative Colitis

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 18 to 75 years
  • diagnosis of ulcerative colitis
  • Currently in remission, remission not longer than 12 months
  • limited quality of life or increased subjective stress level

Exclusion Criteria:

  • Infectious or chronic active ulcerative colitis
  • Taking glucocorticoids or immunosuppressants within the last 3 months, except stable medication using azathioprine
  • colectomy
  • serious psychological disorder (for example: major depression, addiction, schizophrenia)
  • serious comorbid somatic disease (for example: diabetes mellitus, oncological disease)
  • pregnancy
  • participation in stress reduction program or clinical studies to psychological interventions

Sites / Locations

  • Kliniken Essen-Mitte, Knappschafts KrankenhausRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

lifestyle-modification

control group

Arm Description

Once a week for 10 weeks with a circumference of 60 hours with mindfulness-based stress reduction and further process of the Mind / body medicine.

A unique education unit within the scope of 3 hours on the influence of lifestyle factors on the disease and self-help materials for the independent training.

Outcomes

Primary Outcome Measures

Disease-specific quality of life
Inflammatory Bowel Disease Questionnaire (IBD-Q)

Secondary Outcome Measures

Disease-specific quality of life
Inflammatory Bowel Disease Questionnaire (IBD-Q)
Disease-specific quality of life
Inflammatory Bowel Disease Questionnaire (IBD-Q)
Disease-specific quality of life
Inflammatory Bowel Disease Questionnaire (IBD-Q)
Disease activity
Mayo Disease Activity Index (Mayo Score)
Disease activity
Clinical Activity Index (CAI)
Disease activity
Mayo Disease Activity Index (Mayo Score)
Disease activity
Clinical Activity Index (CAI)
Disease activity
Mayo Disease Activity Index (Mayo Score)
Disease activity
Clinical Activity Index (CAI)
Disease activity
Mayo Disease Activity Index (Mayo Score)
Disease activity
Clinical Activity Index(CAI)
Endoscopic index
Endoscopic-Index (sigmoidoscopy)
Endoscopic index
Endoscopic-Index (sigmoidoscopy)
Endoscopic index
Endoscopic-Index (sigmoidoscopy))
Endoscopic index
Endoscopic-Index (sigmoidoscopy)
Histology
Riley Score
Histology
Riley Score
Histology
Riley Score
Histology
Riley Score
Generic quality of life
Short Form (SF) -36 (items) health survey
Generic quality of life
SF-36 health survey
Generic quality of life
SF-36 health survey
Generic quality of life
SF-36 health survey
Anxiety and depression
Hospital Anxiety and Depression Scale (HADS)
Anxiety and depression
Hospital Anxiety and Depression Scale (HADS)
Anxiety and depression
Hospital Anxiety and Depression Scale (HADS)
Anxiety and depression
Hospital Anxiety and Depression Scale (HADS)
Perceived stress
Perceived Stress Scale (PSS)
Perceived stress
Perceived Stress Scale (PSS)
Perceived stress
Perceived Stress Scale (PSS)
Perceived stress
Perceived Stress Scale (PSS)
Irritable Bowel Syndrome Symptoms
IBS Severity Scoring System (IBS-SSS)
Irritable Bowel Syndrome Symptoms
IBS Severity Scoring System (IBS-SSS)
Irritable Bowel Syndrome Symptoms
IBS Severity Scoring System (IBS-SSS)
Irritable Bowel Syndrome Symptoms
IBS Severity Scoring System (IBS-SSS)
Hemogram
leukocyte, hemoglobin, hematocrit, platelet
Hemogram
leukocyte, hemoglobin, hematocrit, platelet
Hemogram
leukocyte, hemoglobin, hematocrit, platelet
Hemogram
leukocyte, hemoglobin, hematocrit, platelet
Blood sedimentation rate
Blood sedimentation rate
Blood sedimentation rate
Blood sedimentation rate
C-reactive protein
C-reactive protein
C-reactive protein
C-reactive protein
faecal calprotectin
faecal calprotectin
faecal calprotectin
faecal calprotectin
faecal lactoferrin
faecal lactoferrin
faecal lactoferrin
faecal lactoferrin
faecal polymorphonuclear (PMN)-elastase
faecal polymorphonuclear elastase
faecal PMN-elastase
faecal polymorphonuclear elastase
faecal PMN-elastase
faecal polymorphonuclear elastase
faecal PMN-elastase
faecal polymorphonuclear elastase
faecal human beta-defensin-2 (hBD-2)
faecal hBD-2
human beta-defensin-2
faecal hBD-2
human beta-defensin-2
faecal hBD-2
human beta-defensin-2
Intestinal microbiota
High-throughput 16S ribosomal ribonucleic acid (rRNA) gene sequencing
Intestinal microbiota
High-throughput 16S rRNA gene sequencing
Intestinal microbiota
High-throughput 16S rRNA gene sequencing
Intestinal microbiota
High-throughput 16S rRNA gene sequencing
Intestinal permeability
LactoseMonitol
Intestinal permeability
LactoseMonitol
Intestinal permeability
LactoseMonitol
Intestinal permeability
LactoseMonitol
Adverse events
Adverse events
Adverse events
Adverse events

Full Information

First Posted
February 10, 2016
Last Updated
May 9, 2017
Sponsor
Universität Duisburg-Essen
search

1. Study Identification

Unique Protocol Identification Number
NCT02721823
Brief Title
Randomized Controlled Trial of Stress Reduction and Lifestyle Modification for Ulcerative Colitis
Acronym
MBMCol
Official Title
Randomized Controlled Trial on the Effect of Stress Reduction and Lifestyle Modification on Disease Activity in Ulcerative Colitis
Study Type
Interventional

2. Study Status

Record Verification Date
May 2017
Overall Recruitment Status
Unknown status
Study Start Date
March 2016 (undefined)
Primary Completion Date
October 2019 (Anticipated)
Study Completion Date
October 2019 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Universität Duisburg-Essen

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Patients with ulcerative colitis often suffer significant limitations to their quality of life, which are also conditioned by particular stress and psychosocial accompanying symptoms of the disease. A multimodal program for stress-reduction and lifestyle-modification has been shown to be effective in promoting the quality of life. The study will examine the promotion of the quality of life of patients with ulcerative colitis and the positive Influence on stress, psychological symptoms and physiological parameters. 92 patients with ulcerative colitis will be randomized in an Intervention group and a control group for 10 weeks. The primary outcome is the disease-specific quality of life, the secondary outcomes are stress, psychological symptoms, inflammatory parameters, disease activity parameters, bowel parameter and the microbiome.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ulcerative Colitis

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
92 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
lifestyle-modification
Arm Type
Experimental
Arm Description
Once a week for 10 weeks with a circumference of 60 hours with mindfulness-based stress reduction and further process of the Mind / body medicine.
Arm Title
control group
Arm Type
Active Comparator
Arm Description
A unique education unit within the scope of 3 hours on the influence of lifestyle factors on the disease and self-help materials for the independent training.
Intervention Type
Behavioral
Intervention Name(s)
lifestyle-modification
Intervention Description
The group intervention is carried out once a week for 10 weeks for a total of 60 hours with elements of mindfulness-based stress reduction (MBSR) and further process of the mind / body medicine. In this project, this program will be adapted to the specific needs of colitis patients.
Intervention Type
Behavioral
Intervention Name(s)
Control group
Intervention Description
Participants in this group receive a one-time education unit within the scope of 3 hours on the influence of lifestyle factors on the disease, also self-help materials for independent training offered. Following the follow-up measure also this group is given the opportunity to participate in the multimodal stress reduction- and lifestyle modification program.
Primary Outcome Measure Information:
Title
Disease-specific quality of life
Description
Inflammatory Bowel Disease Questionnaire (IBD-Q)
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Disease-specific quality of life
Description
Inflammatory Bowel Disease Questionnaire (IBD-Q)
Time Frame
48 weeks
Title
Disease-specific quality of life
Description
Inflammatory Bowel Disease Questionnaire (IBD-Q)
Time Frame
60 weeks
Title
Disease-specific quality of life
Description
Inflammatory Bowel Disease Questionnaire (IBD-Q)
Time Frame
108 weeks
Title
Disease activity
Description
Mayo Disease Activity Index (Mayo Score)
Time Frame
12 weeks
Title
Disease activity
Description
Clinical Activity Index (CAI)
Time Frame
12 weeks
Title
Disease activity
Description
Mayo Disease Activity Index (Mayo Score)
Time Frame
48 weeks
Title
Disease activity
Description
Clinical Activity Index (CAI)
Time Frame
48 weeks
Title
Disease activity
Description
Mayo Disease Activity Index (Mayo Score)
Time Frame
60 weeks
Title
Disease activity
Description
Clinical Activity Index (CAI)
Time Frame
60 weeks
Title
Disease activity
Description
Mayo Disease Activity Index (Mayo Score)
Time Frame
108 weeks
Title
Disease activity
Description
Clinical Activity Index(CAI)
Time Frame
108 weeks
Title
Endoscopic index
Description
Endoscopic-Index (sigmoidoscopy)
Time Frame
12 weeks
Title
Endoscopic index
Description
Endoscopic-Index (sigmoidoscopy)
Time Frame
48 weeks
Title
Endoscopic index
Description
Endoscopic-Index (sigmoidoscopy))
Time Frame
60 weeks
Title
Endoscopic index
Description
Endoscopic-Index (sigmoidoscopy)
Time Frame
108 weeks
Title
Histology
Description
Riley Score
Time Frame
12 weeks
Title
Histology
Description
Riley Score
Time Frame
48 weeks
Title
Histology
Description
Riley Score
Time Frame
60 weeks
Title
Histology
Description
Riley Score
Time Frame
108 weeks
Title
Generic quality of life
Description
Short Form (SF) -36 (items) health survey
Time Frame
12 weeks
Title
Generic quality of life
Description
SF-36 health survey
Time Frame
48 weeks
Title
Generic quality of life
Description
SF-36 health survey
Time Frame
60 weeks
Title
Generic quality of life
Description
SF-36 health survey
Time Frame
108 weeks
Title
Anxiety and depression
Description
Hospital Anxiety and Depression Scale (HADS)
Time Frame
12 weeks
Title
Anxiety and depression
Description
Hospital Anxiety and Depression Scale (HADS)
Time Frame
48 weeks
Title
Anxiety and depression
Description
Hospital Anxiety and Depression Scale (HADS)
Time Frame
60 weeks
Title
Anxiety and depression
Description
Hospital Anxiety and Depression Scale (HADS)
Time Frame
108 weeks
Title
Perceived stress
Description
Perceived Stress Scale (PSS)
Time Frame
12 weeks
Title
Perceived stress
Description
Perceived Stress Scale (PSS)
Time Frame
48 weeks
Title
Perceived stress
Description
Perceived Stress Scale (PSS)
Time Frame
60 weeks
Title
Perceived stress
Description
Perceived Stress Scale (PSS)
Time Frame
108 weeks
Title
Irritable Bowel Syndrome Symptoms
Description
IBS Severity Scoring System (IBS-SSS)
Time Frame
12 weeks
Title
Irritable Bowel Syndrome Symptoms
Description
IBS Severity Scoring System (IBS-SSS)
Time Frame
48 weeks
Title
Irritable Bowel Syndrome Symptoms
Description
IBS Severity Scoring System (IBS-SSS)
Time Frame
60 weeks
Title
Irritable Bowel Syndrome Symptoms
Description
IBS Severity Scoring System (IBS-SSS)
Time Frame
108 weeks
Title
Hemogram
Description
leukocyte, hemoglobin, hematocrit, platelet
Time Frame
12 weeks
Title
Hemogram
Description
leukocyte, hemoglobin, hematocrit, platelet
Time Frame
48 weeks
Title
Hemogram
Description
leukocyte, hemoglobin, hematocrit, platelet
Time Frame
60 weeks
Title
Hemogram
Description
leukocyte, hemoglobin, hematocrit, platelet
Time Frame
108 weeks
Title
Blood sedimentation rate
Time Frame
12 weeks
Title
Blood sedimentation rate
Time Frame
48 weeks
Title
Blood sedimentation rate
Time Frame
60 weeks
Title
Blood sedimentation rate
Time Frame
108 weeks
Title
C-reactive protein
Time Frame
12 weeks
Title
C-reactive protein
Time Frame
48 weeks
Title
C-reactive protein
Time Frame
60 weeks
Title
C-reactive protein
Time Frame
108 weeks
Title
faecal calprotectin
Time Frame
12 weeks
Title
faecal calprotectin
Time Frame
48 weeks
Title
faecal calprotectin
Time Frame
60 weeks
Title
faecal calprotectin
Time Frame
108 weeks
Title
faecal lactoferrin
Time Frame
12 weeks
Title
faecal lactoferrin
Time Frame
48 weeks
Title
faecal lactoferrin
Time Frame
60 weeks
Title
faecal lactoferrin
Time Frame
108 weeks
Title
faecal polymorphonuclear (PMN)-elastase
Description
faecal polymorphonuclear elastase
Time Frame
12 weeks
Title
faecal PMN-elastase
Description
faecal polymorphonuclear elastase
Time Frame
48 weeks
Title
faecal PMN-elastase
Description
faecal polymorphonuclear elastase
Time Frame
60 weeks
Title
faecal PMN-elastase
Description
faecal polymorphonuclear elastase
Time Frame
108 weeks
Title
faecal human beta-defensin-2 (hBD-2)
Time Frame
12 weeks
Title
faecal hBD-2
Description
human beta-defensin-2
Time Frame
48 weeks
Title
faecal hBD-2
Description
human beta-defensin-2
Time Frame
60 weeks
Title
faecal hBD-2
Description
human beta-defensin-2
Time Frame
108 weeks
Title
Intestinal microbiota
Description
High-throughput 16S ribosomal ribonucleic acid (rRNA) gene sequencing
Time Frame
12 weeks
Title
Intestinal microbiota
Description
High-throughput 16S rRNA gene sequencing
Time Frame
48 weeks
Title
Intestinal microbiota
Description
High-throughput 16S rRNA gene sequencing
Time Frame
60 weeks
Title
Intestinal microbiota
Description
High-throughput 16S rRNA gene sequencing
Time Frame
108 weeks
Title
Intestinal permeability
Description
LactoseMonitol
Time Frame
12 weeks
Title
Intestinal permeability
Description
LactoseMonitol
Time Frame
48 weeks
Title
Intestinal permeability
Description
LactoseMonitol
Time Frame
60 weeks
Title
Intestinal permeability
Description
LactoseMonitol
Time Frame
108 weeks
Title
Adverse events
Time Frame
12 weeks
Title
Adverse events
Time Frame
48 weeks
Title
Adverse events
Time Frame
60 weeks
Title
Adverse events
Time Frame
108 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 18 to 75 years diagnosis of ulcerative colitis Currently in remission, remission not longer than 12 months limited quality of life or increased subjective stress level Exclusion Criteria: Infectious or chronic active ulcerative colitis Taking glucocorticoids or immunosuppressants within the last 3 months, except stable medication using azathioprine colectomy serious psychological disorder (for example: major depression, addiction, schizophrenia) serious comorbid somatic disease (for example: diabetes mellitus, oncological disease) pregnancy participation in stress reduction program or clinical studies to psychological interventions
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jost Langhorst, Prof. Dr. med.
Phone
020117425012
Email
j.langhorst@kliniken-essen-mitte.de
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jost Langhorst, Prof. Dr. med.
Organizational Affiliation
Kliniken Essen-Mitte
Official's Role
Principal Investigator
Facility Information:
Facility Name
Kliniken Essen-Mitte, Knappschafts Krankenhaus
City
Essen
State/Province
NRW
ZIP/Postal Code
45276
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jost Langhorst, Prof. Dr.
Phone
49-201-174 25012
Email
j.langhorst@kliniken-essen-mitte.de

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
35260152
Citation
Schlee C, Uecker C, Bauer N, Koch AK, Langhorst J. Multimodal stress reduction and lifestyle modification program for patients with ulcerative colitis: a qualitative study. BMC Complement Med Ther. 2022 Mar 8;22(1):60. doi: 10.1186/s12906-021-03478-w.
Results Reference
derived

Learn more about this trial

Randomized Controlled Trial of Stress Reduction and Lifestyle Modification for Ulcerative Colitis

We'll reach out to this number within 24 hrs